Protocol Title: Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin Lymphoma

Sponsor: AbbVie

Protocol Number: M22-132

Key Criteria

  • Non-Hodgkins Lymphoma with CD20+ disease (de novo or histologically transformed from follicular lymphoma or nodal marginal zone lymphoma) 
    • DLBCL, not otherwise specified
    • High grade B-cell lymphoma with MYC and BCL-2 and/or BCL-6 translocations per WHO 2016
      • Note: High-Grade B cell lymphomas NOS or other double/triple-hit lymphomas (with histologies not consistent with DLBCL) are not eligible
    • Follicular Lymphoma Grade 3B

Talking Points

Scroll to Top